Abstract-Recent studies have challenged the notion that "lower is better" for blood pressure in relation to vascular events and mortality in patients with vascular disease, whereas practice guidelines currently recommend to lower blood pressure to Ͻ130/80 mm Hg. We reassessed this J-curved relationship between blood pressure and cardiovascular events and all-cause mortality in patients with various manifestations of vascular disease. For this purpose, 5788 patients with symptomatic vascular disease enrolled in the Secondary Manifestations of Arterial Disease Study were followed-up for the occurrence of new vascular events (ie, myocardial infarction, stroke, or vascular death) and all-cause mortality. During a median of 5.0 years (interquartile range: 2.6 -8.1 years), 788 patients experienced a new vascular event, and 779 died. Overall, the covariateadjusted relationship between mean baseline systolic, diastolic, or pulse pressure and the occurrence of vascular events followed a J-curve with increased event rates above and below the nadir blood pressure of 143/82 mm Hg. A similar nonlinear relationship was found for diastolic pressure and all-cause mortality. Elevated blood pressure was not associated with increased morbidity and mortality in patients with recently diagnosed coronary artery disease, Ն65 years, and having Ͼ60 mm Hg pulse pressure. Importantly, especially in these subgroups, low blood pressure could also be a symptom rather than a cause of disease. Blood pressure level below and above 143/82 mm Hg is, thus, an independent risk factor for recurrent events in patients with manifest vascular disease. Uncertainty of whether this association is causal provides a strong rationale for trials evaluating blood pressure treatment targets. (Hypertension. 2012;59:00-00.) • Online Data Supplement Key Words: hypertension Ⅲ blood pressure Ⅲ J-curve Ⅲ vascular disease Ⅲ secondary prevention R ecent trials and observational studies have challenged the notion that lower is better for blood pressure management in patients with a history of manifest vascular disease. High blood pressure has since long been recognized as a strong and modifiable risk factor for cardiovascular disease and mortality. 1 In individuals without manifest vascular disease, blood pressure is directly related to vascular and overall mortality, without any evidence of a threshold down to Ն115/75 mm Hg. 1 Moreover, blood pressure-lowering therapy reduces the risk for cardiovascular events in patients with and without manifest vascular disease. [2] [3] [4] The consensus target for blood pressure lowering therapy is Ͻ140/90 mm Hg. 5, 6 In addition, the American Heart Association stated that more stringent blood pressure control down to Ͻ130/80 mm Hg is advised for patients with demonstrated coronary artery disease (CAD) or risk equivalents, including carotid artery disease and peripheral artery disease (PAD). 6 Yet, more and more cohort studies suggest that blood pressure below a certain nadir is associated with adverse health outcomes in patients with a history of manifest vascular disease. [7] [8] [9] [10] [11] [12] These findings have raised the concern that stringent blood pressure targets for patients with manifest vascular disease, based on observations in patients without vascular disease, may be inadequate. Against this background, we reassessed the J-shaped association between blood pressure level and cardiovascular events and mortality in an unselected population of patients with clinically manifest vascular disease and aimed to find the most likely explanations.
R ecent trials and observational studies have challenged the notion that lower is better for blood pressure management in patients with a history of manifest vascular disease. High blood pressure has since long been recognized as a strong and modifiable risk factor for cardiovascular disease and mortality. 1 In individuals without manifest vascular disease, blood pressure is directly related to vascular and overall mortality, without any evidence of a threshold down to Ն115/75 mm Hg. 1 Moreover, blood pressure-lowering therapy reduces the risk for cardiovascular events in patients with and without manifest vascular disease. [2] [3] [4] The consensus target for blood pressure lowering therapy is Ͻ140/90 mm Hg. 5, 6 In addition, the American Heart Association stated that more stringent blood pressure control down to Ͻ130/80 mm Hg is advised for patients with demonstrated coronary artery disease (CAD) or risk equivalents, including carotid artery disease and peripheral artery disease (PAD). 6 Yet, more and more cohort studies suggest that blood pressure below a certain nadir is associated with adverse health outcomes in patients with a history of manifest vascular disease. [7] [8] [9] [10] [11] [12] These findings have raised the concern that stringent blood pressure targets for patients with manifest vascular disease, based on observations in patients without vascular disease, may be inadequate. Against this background, we reassessed the J-shaped association between blood pressure level and cardiovascular events and mortality in an unselected population of patients with clinically manifest vascular disease and aimed to find the most likely explanations.
Methods

Study Population
Patients originated from the Secondary Manifestations of Arterial Disease Study. 13 Study patients were newly referred with a history or recent diagnosis of manifest atherosclerotic disease and were screened noninvasively for manifestations of atherosclerotic diseases and risk factors other than the qualifying diagnosis. The ethics committee of the University Medical Center Utrecht approved the study, and all of the participants gave their written informed consent.
For the current study, we used data of 5788 patients enrolled between January 1996 and February 2010 with either a history or a recent diagnosis of clinically manifest vascular disease. CAD was defined as a clinical diagnosis of angina pectoris, myocardial infarction, cardiac arrest, or coronary revascularization (coronary bypass surgery or coronary angioplasty). Cerebrovascular disease (CVD) was defined as a clinical diagnosis of a recent ischemic or hemorrhagic stroke, transient ischemic attack, amaurosis fugax, or retinal infarction. PAD was defined as a symptomatic and documented obstruction of distal arteries of the leg, a revascularization procedure of the leg (percutaneous transluminal angioplasty, bypass, or amputation), or an abdominal aortic aneurysm with an anteroposterior diameter of Ն3 cm. A recent diagnosis was assumed when any of the above vascular events was the primary reason for referral to the study center. In addition, a history of vascular disease was also assumed on the basis of self-report using a standardized questionnaire on medical history.
Baseline Examination
Participants completed a questionnaire on cardiovascular history, risk factors, and current medication use. 13 Blood pressure was measured every 4 minutes during a total of 25 minutes in supine position at the right brachial artery until March 1999 and 2 times in the sitting position at the right and left upper arms from March 1999 onward. In both situations, the highest mean of the blood pressure measurements on one arm was taken. 13 Physical examination also included measurement of anthropometric indices (weight, height, and waist circumference). Fasting venous blood and urine samples were taken to determine serum lipids, glucose, creatinine, and highsensitivity C-reactive protein.
Follow-Up
Patients were biannually asked to complete a questionnaire on hospitalizations and outpatient clinic visits. Outcomes of interest for this study were first occurrence of myocardial infarction, ischemic stroke, vascular death, and a composite of these events (all vascular events). All-cause mortality was recorded as well. Definitions of events are shown in Table S1 (please see the online Data Supplement at http://hyper.ahajournals.org). When a possible event was reported, hospital discharge letters and results of relevant laboratory and radiology examinations were collected. Death and cause of death were reported by relatives of the participant, the general practitioner, or the vascular specialist. Based on the information from the questionnaire and/or the family, all of the events were adjudicated by 3 members of the Secondary Manifestations of Arterial Disease Study End Point Committee, composed of physicians from different departments. Follow-up duration (years) was defined as the period between study enrollment and first cardiovascular event or death from any cause, date of loss to follow-up, or the preselected date of March 1, 2010. Of the 5788 participants, 197 (3.4%) were lost to follow-up because of migration or discontinuation of the study.
Data Analyses
Baseline characteristics were compared among mean systolic blood pressure (SBP) and mean diastolic blood pressure (DBP) categories. Single imputation methods were used to reduce missing data for serum high density lipoprotein cholesterol (nϭ48; 0.8%), serum total cholesterol (nϭ32; 0.6%), current smoking status (nϭ24; 0.4%), pulse pressure (PP; nϭ16; 0.3%), DBP (nϭ14; 0.2%), and SBP (nϭ8; 0.1%), because complete case analysis leads to loss of statistical power and possibly to bias. 14 The relationship between baseline mean blood pressure (ie, SBP, DBP, and PP) and cardiovascular events and all-cause mortality was assessed by Cox proportional hazards regression models, including linear and quadratic terms for blood pressure. Analyses were adjusted for age, sex, history of CAD, history of CVD, history of PAD, presence of type 2 diabetes mellitus, current smoking status, and serum levels of total cholesterol and high-density lipoprotein cholesterol. The P values of the overall and nonlinear effects of baseline mean blood pressure on the occurrence of vascular events and mortality were based on the 2 statistic. The nadir blood pressure was calculated using the ␦ method, as the coefficient of the linear term divided by minus 2 times the coefficient of the quadratic term. For graphic representation of the relationship between blood pressure and cardiovascular events and mortality, hazard ratios and 95% CIs were plotted, taking 140 mm Hg SBP, 80 mm Hg DBP, and 60 mm Hg PP as a reference. These reference levels approximate the mean SBP (141 mm Hg), DBP (82 mm Hg), and PP (60 mm Hg) of the study population. The plotted hazard ratios were based on the covariate adjusted Cox proportional hazards model with a restricted cubic splines transformation of blood pressure, with 3 knots placed at 110, 150, and 170 mm Hg for SBP; 60, 80, and 100 mm Hg for DBP; and 40, 60, and 80 mm Hg for PP.
Interaction tests were performed using the models described above for the following covariates: sex, age (Ͼ65 years versus Յ65 years), presence of type 2 diabetes mellitus, blood pressure-lowering medication use, PP (Ͼ60 versus Յ60 mm Hg), and history or recent diagnosis of CAD, CVD, or PAD. To account for multiple testing, the P values of the interaction variables were adjusted using the Benjamini and Hochberg method. 15 When significant interaction was found, the analyses were stratified according to the effect modifying characteristic.
Sensitivity analyses were performed to evaluate whether the nonlinear effects were influenced by outlier values for blood pressure through exclusion of patients having an SBP level Ͻ110 mm Hg (nϭ60) or Ͼ200 mm Hg (nϭ222). We also evaluated the likelihood of reverse causality. Reverse causality, referring to the possibility that low blood pressure may be a consequence rather than a cause of poor health conditions (eg, congestive heart failure or malignancy), is a frequently mentioned explanation for low blood pressureassociated morbidity and mortality. 10, 16, 17 Because reverse causality, if present, affects short-term rather than long-term results, regression analyses were repeated excluding any patients who were followed up for Ͻ1 year. Moreover, we compared causes of death for subjects with mean baseline SBP level lower and higher than 140 mm Hg, mean baseline DBP lower and higher than 80 mm Hg, and mean baseline PP lower than and higher than 60 mm Hg using a Pearson 2 test. Causes of death were categorized as vascular death, progressive heart failure, malignancy, or other. Statistical analyses were performed with the open source statistical software package R, version 2.13.0.
Results
Of the 5788 patients included in the analyses, 2742 had a history or recent diagnosis of CAD, 1178 had a history or recent diagnosis of CVD, 723 had a history or recent diagnosis of PAD, and 1145 had Ͼ1 of these diagnoses. The Table and Table S2 (please see the online Data Supplement) summarize the baseline characteristics by mean baseline SBP and DBP categories, respectively. Patients with low SBP were younger; leaner; less likely to have a history of type 2 diabetes mellitus, CVD, or PAD; and less likely to use diuretics, angiotensin-converting enzyme inhibitors, or calcium antagonists. They were more likely to be smokers, have a history of CAD, and to use ␤-blockers, platelet inhibitors, and lipid-lowering agents. Patients with low DBP were also younger and less likely to have a history of CVD or PAD or to use diuretics or angiotensin-converting enzyme inhibitors and more likely to be smokers, have a history of CAD, and to use ␤-blockers and platelet inhibitors.
During a median follow-up of 5.0 years (interquartile range: 2.6 -8.1 years; 31 563 person-years), 779 participants died (of whom 477 from a vascular cause), 234 experienced a stroke, and 409 experienced a myocardial infarction. The composite end point of myocardial infarction, stroke, or vascular death occurred in 788 patients.
Vascular Events
The relationship between SBP and the incidence of all vascular events followed a J-shaped curve, with increased hazard rates at low and high SBPs. This was initially assessed by a Cox proportional hazards model with restricted cubic splines ( Figure 1A ) and confirmed by a nonlinear Cox proportional hazards model including linear and quadratic SBP terms (PϽ0.01; nonlinear SBP term PϽ0.01). Similarly, the relationship between DBP and the incidence of all vascular events followed a J-shaped curve ( Figure 1B ; PϽ0.01; nonlinear DBP term PϽ0.01). Furthermore, a J-shape was also demonstrated in the relationship between PP and the incidence of all vascular events ( Figure 1C ; PϽ0.01; nonlinear PP term PϽ0.01). The nadir blood pressure, where the event rate was lowest, was 143/82 mm Hg, and the nadir PP was 62 mm Hg. Blood pressure, mm Hg Systolic blood pressure 120 (8) 136 (3) 149 (6) 176 (13) Diastolic blood pressure 74 (8) 80 (8) 85 (9) 93 (12) Pulse pressure 46 (8) 56 (8) 65 (10) 83 (14) Antihypertensive medication use, % CAD indicates coronary artery disease; CVD, cerebrovascular disease; PAD, peripheral artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Hs-CRP, high-sensitivity C-reactive protein; BMI, body mass index; eGFR, estimated glomerular filtration rate. Data are mean (SD), percentage of group, and median (interquartile range).
*eGFR is estimated by the Modification of Diet in Renal Disease equation.
SBP level was positively related to the occurrence of stroke (please see Figure S1 ; PϽ0.01); however, no nonlinearity was observed (Pϭ0.08). Low SBP level, thus, was not associated with increased occurrence of stroke. No association was found between mean baseline SBP level and the occurrence of myocardial infarction ( Figure S2 
All-Cause Mortality
No relationship between SBP and the incidence of all-cause mortality was observed ( Figure 1D ; Pϭ0.10; nonlinear SBP term Pϭ0.10). The relationship between DBP and the incidence of all-cause mortality, however, was J-shaped ( Figure  1E term Pϭ0.18). The nadir blood pressure, where the mortality rate was lowest, was 140/84 mm Hg, and the nadir PP was 54 mm Hg.
Interaction
Results of the interaction tests are shown in Table S3 . The effect of blood pressure on vascular events and mortality was modified by the presence or absence of recently diagnosed CAD, age (Ͼ65 versus Յ65 years), and PP (Ͼ60 versus Յ60 mm Hg). No sex-based differences were present. Figure  2 shows that, in patients with recently diagnosed CAD, elevated blood pressure was not associated with increased morbidity and mortality. Similarly, Figures S4 and S5 show that this is also true for patients Ͼ65 years for patients whose PP was Ͼ60 mm Hg. Notably, especially in these subgroups of patients, low blood pressure could also be a symptom rather than a cause of disease.
Sensitivity Analyses
The shape of the relationship between blood pressure level and vascular events and mortality did not change after omission of patients having SBP Ͻ110 mm Hg or Ͼ200 mm Hg, nor after exclusion of patients who were followed-up for Ͻ1 year ( Figure S6 ). The relative distribution of causes of death, categorized as vascular death, heart failure, malignancy, or other, was similar for subjects with SBP Ͻ140 mm Hg and Ն140 Figure S7 ).
Discussion
Our findings contribute to a growing body of evidence that lower blood pressure levels are not always better in patients with clinically manifest vascular disease. This was first observed by Cruickshank 18 in 1988 in patients with CAD or PAD and later confirmed in 1991 among subjects with previous myocardial infarction enrolled in the Framingham Heart Study. 8 More recently, in an observational post hoc analysis of 6400 participants of the International VerapamilTrandolapril Study with CAD and type 2 diabetes mellitus, 
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Blood Pressure J-Curve Revisitedtight blood pressure control (SBP Ͻ130 mm Hg) failed to result in reduced risk for vascular events compared with normal blood pressure control (SBP 130 -140 mm Hg). 9 Extended follow-up of these patients for the occurrence of mortality after the initial study period led to the conclusion that tight blood pressure control was even associated with increased mortality (adjusted hazard ratio: 12 Observational analysis of CAD patients from the Pravastatin or Atorvastatin Evaluation and Infection Therapy Trial revealed that average follow-up blood pressure level of 136/85 mm Hg was related to lowest risk for vascular events and mortality with higher event rates being observed in those with lower blood pressure levels. 10 Similarly, in observational analyses of the Treating to New Targets Trial, which enrolled 10 001 patients with a history of CAD, average blood pressure level of 146/81 mm Hg was associated with lowest risk for vascular events. 7 A nonlinear J-shaped association was observed between both SBP and DBP and the occurrence of vascular events, except between SBP and stroke. Lower blood pressure was also associated with increased all-cause mortality in this study. 7 Randomized trials evaluating blood pressure targets in patients with clinically manifest vascular disease have not been performed to our knowledge. Interestingly, the Action to Control Cardiovascular Risk in Diabetes Trial, a randomized trial evaluating the effect of clinically relevant SBP targets (Յ120 versus Յ140 mm Hg) in patients with type 2 diabetes mellitus, 33.7% of whom had concomitant vascular disease, found that tight blood pressure control was not associated with a reduced rate of a composite outcome of fatal and nonfatal major cardiovascular events despite good contrast in SBP between both groups during follow-up (119.3 versus 133.5 mm Hg). 19 To date, 25 trials evaluated the effect of antihypertensive treatment on prevention of vascular events and all-cause mortality, at least in part, in normotensive subjects with manifest vascular disease. 4 A meta-analysis of these trials and trial-subgroups showed that antihypertensive treatment overall resulted in Ϫ17% (95% CI: Ϫ31% to Ϫ1%) relative risk reduction for vascular events and Ϫ13% (95% CI: Ϫ20% to Ϫ5%) relative risk reduction for all-cause mortality. 4 However, blood pressure difference between the treatment and placebo groups was reported in only 3 of these studies, and there was a statistical significant difference in only 1 study. It is, therefore, uncertain whether these beneficial effects resulted from blood pressure reduction, per se, or from beyond blood pressure effects from treatment.
Mechanisms for Low Blood Pressure-Related Mortality and Vascular Events
In earlier studies, reverse causality has been proposed as an explanation for low blood pressure-related mortality and vascular events. Observations suggestive of reverse causality include that a J-shaped association is seen during short but not during prolonged follow-up 20 or that an initially present J-shaped or inverse association becomes linear and more positive after exclusion of subjects having congestive heart failure. 21 In the present study, sensitivity analyses showed that exclusion of subjects with Ͻ1 year of follow-up did not alter the shape of the J-curve. We did not exclude patients with poor left ventricular ejection fraction at baseline. However, heart failure and malignancy were not more frequently observed as causes of death in subjects with low baseline blood pressure. Yet, low blood pressure-associated vascular event and mortality risk were more prominent in patients having PP Ͼ60 mm Hg. Importantly, the combination of decreased DBP and increased PP is thought to result from progression of atherosclerosis, leading to vascular stiffness. 22 The observed interaction with PP, therefore, makes the reverse causality hypothesis more plausible. Moreover, high SBP was even associated with a more favorable prognosis in patients with a recent diagnosis of CAD and not associated with adverse outcome in subjects Ͼ65 years of age. Especially in these patients, elevated blood pressure could be a manifestation of adequate remaining cardiac function and vice versa. In contrast to the results of our sensitivity analyses, the observed interactions, therefore, support the existence of reverse causality.
Secondly, index event bias has been proposed as an explanation for paradoxes in recurrence risk research. 23 This refers to the possibility that studies that select patients based on the occurrence of an index event are prone to be biased toward the null because of the general congruence between risk factors for the index and recurrent events. In case of blood pressure, index event bias could theoretically even lead to observation of reversed effects, because high blood pressure is a treatable risk factor. In other words, high blood pressure in patients with manifest vascular disease could be prognostically advantageous (eg, observed in patients with a recent diagnosis of CAD), because it means that the individual's risk for recurrent events is partly modifiable. Yet, the observed associations in this study remained after adjustment for most known risk factors for cardiovascular disease, such as age, sex, smoking, cholesterol, and history of type 2 diabetes mellitus and previous vascular disease, making index event bias a less likely explanation.
Finally, a causal mechanism explaining low blood pressurerelated mortality and vascular events should be considered. Low blood pressure may predispose to insufficient tissue perfusion, particularly in the presence of atherosclerosis. Most importantly, low blood pressure during cardiac diastole may diminish coronary perfusion and, therefore, put persons at risk for myocardial ischemia. 11 This theory is supported by the fact that low DBP was even more strongly correlated with increased risk for mortality and vascular events than low SBP both in this study and in previous ones. 8, 10, 24 
Strengths and Limitations
The Secondary Manifestations of Arterial Disease Study population, in contrast to most trial cohorts, closely reflects clinical practice. Relevant and objective clinical end points were used, such as myocardial infarction, stroke, and death. The proportion of patients who were lost to follow-up because of migration or discontinuation of the study was very low, reducing the risk for bias. Limitations include that blood pressure was measured only at baseline, whereas intraindividual variation of blood pressure level may have occurred during follow-up. This could have led to underestimation of the true effect size but does not mitigate the finding of a J-shaped association between blood pressure and vascular events and mortality in this study. Moreover, repeat measurements of blood pressure in subgroups of 710 and 382 study participants showed that the mean blood pressure level increased by only 3.0/0.5 mm Hg after 4.0 years (interquartile range: 3.8 -4.3 years) and 3.9/1.5 mm Hg after 10.9 years (interquartile range: 10.8 -11.1), arguing against regression dilution effects. Blood pressure was measured in the supine position only until March 1999. However, measurements in 1141 patients enrolled later showed that supine blood pressure level was, on average, Ϫ1.7/Ϫ1.6 mm Hg lower compared with sitting blood pressure. Therefore, this could have affected the estimated nadir blood pressure values, but this effect is likely to be small. Further limitations include that results from observational studies cannot be adjusted for reverse causality and that recurrent risk research is prone to index event bias.
Conclusions
The association among SBP, DBP, PP, and vascular events and mortality in patients with manifest vascular disease is J-shaped and, thus, nonlinear. Blood pressure level above and below RR 143/82 mm Hg is associated with increased vascular event rate. Elevated blood pressure was not associated with higher vascular event rate and mortality in patients with a recent diagnosis of CAD, Ͼ65 years, and with a PP Ͼ60 mm Hg. Because, especially in these subgroups, low blood pressure could also be a symptom rather than a cause of disease, uncertainty remains as to whether this J-curved relationship is indeed causal.
Perspectives
Blood pressure level above and below RR 143/82 mm Hg should be recognized as an independent risk factor for recurrent events in patients with manifest vascular disease, with the exception of patients with a recent diagnosis of CAD, patients Ͼ65 years, and patients whose PP is Ͼ60 mm Hg. Because observational recurrent risk research is prone to confounding and index event bias, the observation of a J-curve does not invalidate the current guideline recommendation that stringent blood pressure control down to Ͻ130/ 80 mm Hg is advised for patients with demonstrated vascular disease. It provides a strong rationale, however, for trials evaluating blood pressure treatment targets. Table S1 . Definitions of vascular events and mortality
Outcome event Definition
Myocardial infarction At least two of the following criteria:
(i) chest pain for at least 20 min, not disappearing after administration of nitrates;
(ii) ST-elevation > 1 mm in two following leads or a left bundle branch block on the electrocardiogram;
(iii) Creatinine kinase (CK) elevation of at least two times the normal value of CK and a myocardial band-fraction > 5% of the total CK.
Sudden death: unexpected cardiac death occurring within 1 hour after onset of symptoms, or within 24 hours given convincing circumstantial evidence.
ICD-10 code I21
Stroke Relevant clinical features causing an increase in impairment of at least one grade on the modified Rankin scale, accompanied by an infarction or hemorrhage on a repeat CT-scan.
ICD-10 codes I60, I61, I63, and I64
Vascular death
Death from stroke, myocardial infarction, congestive heart failure, or rupture of abdominal aortic aneurysm.
Vascular death from other causes.
Death resulting from ICD-10 codes I60, I61, I63, I64, I21, I50, I71-3, I46-1, and R96
All Vascular Events A composite of stroke, myocardial infarction, retinal infarction, and vascular mortality.
ICD-10 codes I60, I61, I63, I64, I21, I50, I71-3, H34-1, H34-8, and I46-1
All-cause mortality Death from any cause.
Death resulting from ICD-10 codes A00-Y98 (17) 134 (15) 145 (16) 163 (20) Diastolic blood pressure 65 (4) 76 (3) 85 (3) 98 (7) Pulse pressure 58 (17) 58 (15) 60 (16) Pulse Pressure(mmHg) HR (95% CI) All cause mortality Total studypopulation Exclusion of SBP <110 or >200 mmHg Exclusion of <1yr follow -up A-C) Change in estimated effect between systolic pressure (A), diastolic pressure (B), and pulse pressure (C) and vascular events after exclusion of patients having systolic pressure <110 mmHg or >200 mmHg at baseline and after exclusion of patients who were followed-up for <1 year. D-F) Change in estimated effect between systolic pressure (D), diastolic pressure (E), and pulse pressure (F) and all cause mortality after exclusion of patients having systolic pressure <110 mmHg or >200 mmHg at baseline and after exclusion of patients who were followed-up for <1 year. 
